Charles River Laboratories International (CRL) EBT (2009 - 2025)

Charles River Laboratories International's EBT history runs 17 years deep, the most recent figure standing at -$294.1 million for Q4 2025.

• In Q4 2025, EBT fell 35.66% year-over-year to -$294.1 million; the TTM figure through Dec 2025 stood at -$99.5 million (down 206.86% YoY), while the FY2025 annual figure was -$99.5 million, down 206.86% from the prior year.
• EBT was -$294.1 million for Q4 2025 at Charles River Laboratories International, down from $87.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $244.9 million in Q4 2022 to a low of -$294.1 million in Q4 2025.
• Historically, EBT has averaged $83.9 million across 5 years, with a median of $116.3 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBT soared 67.18% in 2022, then plunged 203.87% in 2024.
• A 5-year view of EBT shows it stood at $163.6 million in 2021, then jumped by 49.67% to $244.9 million in 2022, then declined by 14.79% to $208.7 million in 2023, then slumped by 203.87% to -$216.8 million in 2024, then tumbled by 35.66% to -$294.1 million in 2025.
• The last three EBT figures came in at -$294.1 million (Q4 2025), $87.2 million (Q3 2025), and $71.4 million (Q2 2025), per Business Quant data.